Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

25%

Ph not_applicable

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 3Large-scale testing

1(25.0%)

N/ANon-phased studies

3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Other(1)

Detailed Status

Completed3

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 31 (25.0%)

N/A3 (75.0%)

Trials by Status

completed375%

unknown125%

Recent Activity

0 active trials

Showing 4 of 4

unknownnot_applicable

Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition

NCT02255318

completednot_applicable

Clinical Trials (4)

Showing 4 of 4 trials

NCT02255318Not Applicable

Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition

Unknown

NCT02279121Not Applicable

ATAPAC Study (TauroLock Activity in Adult Cancer Patients)

Completed

NCT01101087Not Applicable

Taurolock for Preventing Bacterial Peritonitis During Renal Insufficiency

Completed

NCT00735813Phase 3

Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia

Completed

All 4 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 4